[Novartis] gets rights to [Marina Biotech]'s oligonucleotide technology
20:00 EDT 31 Jul 2012 | Elsevier Business Intelligence
RNAi company [Marina Biotech Inc.] has granted [Novartis AG] a nonexclusive license to its conformationally restricted nucleotide (CRN) technology, which is used in the development of single- and double-stranded oligonucleotide therapeutics. Novarti..
Original Article: [Novartis] gets rights to [Marina Biotech]'s oligonucleotide technology
More From BioPortfolio on "[Novartis] gets rights to [Marina Biotech]'s oligonucleotide technology"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
